©2024 Stanford Medicine
Biologically Focused Therapy of Treatment-Refractory MDS Patients
Not Recruiting
Trial ID: NCT05245032
Purpose
This non interventional study examines the feasibility of using patient specific therapeutic
screening method, ex vivo to enhance current treatment recommendations in a clinically
feasible time frame of 30 days.
Official Title
Biologically Focused Therapy of Treatment Refractory MDS Patients
Stanford Investigator(s)
Peter Greenberg
Professor of Medicine (Hematology), Emeritus
Eligibility
Inclusion Criteria:
- Provide informed consent;
- Myelodysplastic syndrome as defined by WHO classification (see Appendix 2), or MDS/MPN
with >= 5% blasts in the bone marrow or peripheral blood, including chronic
myelomonocytic leukemia (CMML) 1 and 2 by WHO classification
- Relapsed/refractory disease, defined as failed or are ineligible for hypomethylating
agent therapy
- Cytogenetics reported
Exclusion Criteria:
- Hypoplastic MDS
- Patients without adequate marrow samples for ex vivo analysis
Not Recruiting
Contact Information
Stanford University
School of Medicine
300 Pasteur Drive
Stanford,
CA
94305
Jack Taw
650-723-2781